The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype

Haematologica

Volumn 91, Issue 6, 2006, Pages 825-828

  Damiani, Daniela ^a   Tiribelli, Mario ^a   Calistri, Elisabetta ^a   Geromin, Antonella ^a   Chiarvesio, Alexsia ^a   Michelutti, Angela ^a   Cavallin, Margherita ^a   Fanin, Renato ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

AML; BCRP; Normal karyotype; PGP; Prognosis

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CD34 ANTIGEN; CD56 ANTIGEN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION;

ACUTE DISEASE; ADULT; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROGNOSIS; REFERENCE VALUES; RETROSPECTIVE STUDIES;

EID: 33745746801     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Michieli M, Damiani D, Geromin A, Michelutti A, Fanin R, Raspadori D, et al. Overexpression of multidrug resistance associated p170 glycoprotein in acute non-lymphocytic leukemia. Eur J Haematol 1992;48:87-92.
2. Del Poeta G, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996;87:1997-2004.
3. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotheragy. A Southwest Oncology Group study. Blood 1997;89:3323-9.
4. Michieli M, Damiani D, Ermacora A, Masolini P, Raspadori D, Visani G, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br J Haematol 1999; 104:328-35.
5. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-58.
6. Mitelman F. ISCN: An International System for Human Cytogenetic Nomenclature. S Karger, Basel 1995.
7. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-9.
8. Minderman H, Suvannasankha A, O'Loughlin KL, Scheffer GL, Scheper RJ, Robey RW, et al. Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 2002;48:59-65.
9. Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M, Sorrentino BP. Low levels of ABCG2 expression in adult AML blast samples. Blood 2002;100: 4594-601.
10. van der Kolk DM, Vellenga E, Scheffer GL, Müller M, Bates SE, et al. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 2002;99: 3763-70.
11. Raaijmakers MHGP, de Grouw EPLM, Heuver LHH, van der Reijden BA, Jansen JH, Scheper RJ, et al. Breast cancer resistance protein in drug resistance of primitive CD34+CD38- cells in acute myeloid leukemia. Clin Cancer Res 2005;11: 2436-44.
12. van den Heuvel-Eibrink MM, Wiemer EAC, Prins A, Meijerink JPP, Vossebeld PJM, van der Holt B, et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia. Leukemia 2002; 16:833-9.
13. Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nardi G, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 2001;15:1161-4.
14. Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 2005;11: 7764-72.
15. Benderra Z, Faussat AM Sayada L, Perrot JY, Chaoui D, Marie JP, et al. Breast cancer resistance protein and P-glycoprotein in adult 149 acute myeloid leukemia. Clin Cancer Res 2004;10:7896-902.
16. Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100:4372-80.
17. Beran M, Luthra R, Kantarjian H, Estey E. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normalkaryotype. Leuk Res 2004;28:547-50.
18. Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005; 11:1416-24.
19. Baldus CD, Tanner SM, Ruppero AS, Whitman SP, Archer KJ, Marcucci G, et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 2004;102:1613-18.
20. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-66.